Trial Profile
A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 Mg Once Daily for 26 Weeks.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Gastrointestinal disorders; NSAID-induced gastric damage; NSAID-induced gastrointestinal damage; NSAID-induced ulcer
- Focus Registrational; Therapeutic Use
- Acronyms ASTERIX
- Sponsors AstraZeneca
- 11 Mar 2009 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 11 Sep 2008 New trial record.